IMCIVREE™(setmelanotide) Logo

IMCIVREE Logo

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

Format

JPEG

Source

Rhythm Pharmaceuticals, Inc.

Downloads